Key View: Biowearables, specifically continuous glucose monitoring (CGM) products, will move out of the medical device sphere in 2022 and into the mainstream consumer sector. The theme is part of the wider trend toward personalised nutrition and fitness offerings. Initially, CGM biowearable products' route to market will be direct-to-consumer (DTC). Future routes to market will likely include e-commerce and bricks and mortar retail (primarily pharmacies, but with the potential to move to other retailers), life and health insurance providers and via gym membership. This theme originated in the US, with US consumer targeted first, but in 2022 we believe it has the potential to expand through Western Europe and other developed consumer markets.
展开▼
